Mandate

Vinge advises Gränges in conjunction with acquisition of Aluminium Konin

November 28, 2019

Vinge has advised Gränges AB (publ) in connection with the acquisition of Aluminium Konin, a Polish aluminium manufacturer, for SEK 2.3 billion from Boryszew Group. In connection with the transaction, Gränges intends to perform a rights issue for SEK 2 billion. In order to finance the acquisition, Gränges has entered into a bridge financing facility agreement with certain Nordic banks for SEK 2.3 billion.

Gränges is a leading global supplier of rolled aluminium products for heat exchanger applications and other niche markets in Europe, Asia and the United States. The company has a turnover of approximately SEK 13 billion and has approximately 1,800 employees. Aluminium Konin is a Polish manufacturer of rolled aluminium, with a turnover of SEK 3 billion and has approximately 750 employees.

The transaction is conditional upon the consent of the relevant competition authorities.

Vinge’s team primarily consist of Kristian Ford (M&A) together with Pär Remnelid, Johan Wahlbom and Julia Söderdahl (Competition Law), Jesper Schönbeck, Rikard Lindahl and Joel Wahlberg (Capital Markets) as well as Louise Brorsson Salomon and Axel Jansson (Banking and Finance).

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025